A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
A team of investigators sought to determine outcomes from combination low-dose carboplatin plus nab-paclitaxel with concurrent radiotherapy among elderly patients with advanced non-small cell lung cancer.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.